Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Biomedica Plc LSE:OXB London Ordinary Share GB00BDFBVT43 ORD 50P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -7.00 -0.85% 813.00 813.00 815.00 836.00 812.00 836.00 16,989 11:20:36
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 64.1 -20.9 -22.1 - 668

Oxford Biomedica Share Discussion Threads

Showing 43226 to 43246 of 43250 messages
Chat Pages: 1730  1729  1728  1727  1726  1725  1724  1723  1722  1721  1720  1719  Older
DateSubjectAuthorDiscuss
29/10/2020
10:48
3,500 sold at 9:00am again...... until this seller finishes this is where we stay... at best.
dominiccummings
29/10/2020
09:15
Novartis signs deal for gene therapy attack on specific blindnessHTTps://www.yahoo.com/now/novartis-acquires-vedere-bio-novel-061500029.html
pharmaboy3
29/10/2020
08:41
Yescarta sales reduce to $138m hTTp://investors.gilead.com/static-files/aff01ff7-e399-4a73-9b64-f3ad421253da
plutonian
29/10/2020
08:17
$GILD Kite Car T revenue decreased this quarter. $147 Q3 2020
marcusl2
29/10/2020
08:07
data from the UK trials, which could be out in two weeks. New Delhi, October 28 Serum Institute chief Adar Poonawalla today said the Oxford-AstraZeneca vaccine could be ready by as early as December and the first 100 million doses could be available by the first or second quarter of 2021. He did not rule out applying for emergency authorisation of the vaccine saying the decision would depend on the Centre and the safety data from the UK trials, which could be out in two weeks. HTTps://www.tribuneindia.com/news/nation/oxford-vaccine-likely-by-dec-poonawalla-162595
marcusl2
28/10/2020
19:08
tim, You know the sweeps are just a bit of fun - it's like the grand national (but a bit more often). We have some big things going on in the background though, not least a lot of people wondering about the US election. I suspect we have a bit more stability once the outcome of that is know, plus some more on top of that when they stop with the EU play acting on this side of the Atlantic and tell us what is actually already agreed. Even with those two out of the way though, we still have a monster recession waiting to drop on Rishi's plate just as soon as his honeymoon period is over. Time to be thankful if you have some money here in healthcare and not in travel or leisure.
harry s truman
28/10/2020
18:56
Will buy a few more tomorrow.....just to win sweep ......you may have to buy several million to win.. Lol
timax333
28/10/2020
18:54
Will buy a few more tomorrow.....just to win sweep ...lol
timax333
28/10/2020
18:38
tim you old tease, it's certainly not me, though you are definitely in with a chance... 750 robs12 833 KymriahKardashian 840 timax 848 digger 850 antreg 861 avc0nway 865 jasie 869 mr_mike 880 catch007 888 pb3 889 hopeSprings 890 trovax 899 elsol 902 boadicea 911 ewads 916 northstand 920 effham 925 fhasson 941 marcus 975 2upthespurs 987 icejelly 999 riskblue 1010 swans 1031 dmorford 1066 bunlop 1200 sturichardson 1250 gh 1299 sharelog 1313 hst 1380 flc 1400 don corleone 1428 gareth 1959 Abd009
harry s truman
28/10/2020
18:33
Sweep update....who is in the running harry??
timax333
28/10/2020
15:49
FTSE tanking 200+ points - 5550!..... so holding up pretty fine here
trovax
28/10/2020
11:41
Freddie, Qu 1: "So the question is is immunity to Covid created by antibodies or T cells or both?" Ans: Both. Antibody (of several types) attacks the virus coat while T-cells attack any cells infected that are showing virus proteins on its surface. Both B-cells (making antibody) and T-cells SHOULD produce memory cells that last a long time (years possibly) and spring into action much more quickly upon reinfection. Note that the reduction in COVID-antibody concentration in body fluids over time DOES NOT necessarily mean that B- and T-memory cells are any less ready for subsequent infections. Qu 2: "I understand some viruses can swap "genetic" material, f knows how". Ans: If two viruses, with slightly different genetic material, infect the same cell then, when they duplicate those genes, said genes have no way of knowing "who" was the original virus parent. So, upon assembly of the virus components (perhaps from hundreds of individual viruses) genetic material can get mixed up so 'blends" occur in the offspring viruses before the genes are assembled into the final virus protein coating. That's one way,
small crow
28/10/2020
09:13
No noseplugs.
freddie ferret
28/10/2020
09:09
Did you wear a waste coat to the interview Freddie?
marcusl2
28/10/2020
09:03
FWIIW. Many years ago I went for a job at a sewage works.
freddie ferret
28/10/2020
09:00
It still appears that there is a big seller..... 3,500 this morning
dominiccummings
28/10/2020
08:58
Freddie.... my mind boggles at the extent of your trivia knowledge.
dominiccummings
28/10/2020
00:04
Re sewage, has anybody seen any info on whether rats can get or carry this bloody disease. Again sewage works operate by spraying sewage onto pumice where oxygen and nitrifying bacteria convert the ammonia urea component to nitrite and then ultimately nitrate. However spraying liquids containing Covid does not seem a good idea to me. If you can smell a sewage works you can also possibly be breathing some of the spray. Re the mutation issue, this virus is reluctant to mutate in a major way, however this is a global issue. Remember the second wave of Spanish flu. :((
freddie ferret
27/10/2020
17:59
Interesting partnership Merck signed deal with small British company 4D.Apparently keytruda far more effective with tailored mictobiomed gut bacteria .Bacteria act as a channel for keytruda .HTTps://www.4dpharmaplc.com/en/newsroom/press-releases/4d-pharma-collaborates-msd-live-biotherapeutics-vaccinesMight be interesting pathway for us ?
pharmaboy3
27/10/2020
15:07
Axovant Gene Therapies Ltd is due to present at its virtual Parkinson's disease R&D day individual patient-level data from Cohort 2 of the Phase 2 SUNRISE-PD study that is evaluating its AXO-Lenti-PD gene therapy for the treatment of Parkinson's disease (Friday)
marcusl2
27/10/2020
14:48
Sanofi Gene therapy research in hemophilia A type of retrovirus called a lentivirus are being investigated as a DNA delivery service. Sanofi scientists are pursuing lentiviruses as delivery vehicles because24: They are large and can carry a lot of information: They are big enough to hold both the corrected DNA sequence of factor VIII, biochemical switches to turn them on or off, and biological information that would prevent white blood cells from attacking the retrovirus. They can integrate into the genome in the liver cells, so that when the cells divide the corrected DNA is reproduced consistently. This is one of many experimental approaches to gene therapy at Sanofi. HTTps://www.sanofi.com/en/science-and-innovation/stories/science-behind-sanofis-hemophilia-pipeline
marcusl2
Chat Pages: 1730  1729  1728  1727  1726  1725  1724  1723  1722  1721  1720  1719  Older
ADVFN Advertorial
Your Recent History
LSE
OXB
Oxford Bio..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201029 11:36:24